➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
Express Scripts
McKesson
Harvard Business School
Dow

Last Updated: April 20, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR MELOXICAM

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Meloxicam

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00034853 Meloxicam [Mobic] in Juvenile Rheumatoid Arthritis (JRA) Completed Boehringer Ingelheim Phase 3 2000-12-01 To obtain safety, efficacy, pharmacokinetic and dosing information for meloxicam oral suspension in children with Juvenile Rheumatoid Arthritis (JRA)
NCT00042068 A Multi-Center Trial to Compare Three Doses of Meloxicam and Placebo in Patients With Rheumatoid Arthritis Completed Boehringer Ingelheim Phase 3 2002-06-01 A 12-week trial consisting of 5 visits (6 if follow up is needed) to find out how effective and safe three different doses of meloxicam are compared with placebo in Rheumatoid Arthritis. Patient will take one dose of study medication daily.
NCT00152919 Mobicox: Study of Meloxicam to Reduce Prostate Swelling in Permanent Seed Prostate Brachytherapy Completed Princess Margaret Hospital, Canada Phase 3 2004-02-01 Swelling of the prostate can occur during and after a brachytherapy. This swelling can cause urinary problems ranging from difficulty voiding to urinary retention. The purpose of this study is to investigate whether Mobicox started one week before brachytherapy and then continued afterwards is more effective in reducing the risk of needing a catheter than Mobicox given only afterwards.
NCT00152919 Mobicox: Study of Meloxicam to Reduce Prostate Swelling in Permanent Seed Prostate Brachytherapy Completed University Health Network, Toronto Phase 3 2004-02-01 Swelling of the prostate can occur during and after a brachytherapy. This swelling can cause urinary problems ranging from difficulty voiding to urinary retention. The purpose of this study is to investigate whether Mobicox started one week before brachytherapy and then continued afterwards is more effective in reducing the risk of needing a catheter than Mobicox given only afterwards.
NCT00239382 A Study to Compare Meloxicam IM Once Daily Versus Meloxicam Orally Once Daily in Patients With Rheumatoid Arthritis Completed Boehringer Ingelheim Phase 3 2004-07-01 The objective of this trial was to assess the efficacy and safety of 15 mg meloxicam i.m. once daily compared with 15 mg meloxicam tablets once daily p.o. in patients with Rheumatoid arthritis over a time period of 7 days.
NCT00239395 A Study to Compare Meloxicam IM Once Daily and Meloxicam Administered Orally Once Daily in Patients With Osteoarthritis Completed Boehringer Ingelheim Phase 3 2004-07-01 The objective of this trial was to assess the efficacy and safety of 7.5 mg meloxicam i.m. once daily compared with 7.5 mg meloxicam tablets once daily p.o. in patients with osteoarthritis over a time period of 7 days.
NCT00279747 A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension in Juvenile Rheumatoid Arthritis (JRA/JIA) Completed Boehringer Ingelheim Phase 3 2000-09-01 A one year double-blind trial to investigate the efficacy and safety of meloxicam oral suspension 0.25 mg/kg and 0.125 mg/kg administered once daily in comparison to naproxen oral suspension 5 mg/kg administered twice daily in children with Juvenile Rheumatoid Arthritis.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Meloxicam

Condition Name

Condition Name for Meloxicam
Intervention Trials
Healthy 18
Osteoarthritis 9
Arthritis, Rheumatoid 7
Migraine 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Meloxicam
Intervention Trials
Osteoarthritis 16
Arthritis, Rheumatoid 10
Osteoarthritis, Knee 9
Arthritis 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Meloxicam

Trials by Country

Trials by Country for Meloxicam
Location Trials
United States 125
Japan 20
China 15
Brazil 9
Canada 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Meloxicam
Location Trials
Massachusetts 9
Florida 8
Texas 8
Pennsylvania 7
New York 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Meloxicam

Clinical Trial Phase

Clinical Trial Phase for Meloxicam
Clinical Trial Phase Trials
Phase 4 12
Phase 3 23
Phase 2/Phase 3 2
[disabled in preview] 44
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Meloxicam
Clinical Trial Phase Trials
Completed 53
Recruiting 16
Not yet recruiting 4
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Meloxicam

Sponsor Name

Sponsor Name for Meloxicam
Sponsor Trials
Boehringer Ingelheim 29
Axsome Therapeutics, Inc. 3
Iroko Pharmaceuticals, LLC 3
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Meloxicam
Sponsor Trials
Industry 54
Other 41
NIH 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Boehringer Ingelheim
Mallinckrodt
Colorcon
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.